Lionco Pharmaceutical Group Co.,Ltd.

Informe acción SHSE:603669

Capitalización de mercado: CN¥4.1b

Lionco Pharmaceutical GroupLtd Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Ling Ping Tao

Chief Executive Officer (CEO)

CN¥660.0k

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEOno data
Participación del CEO6.8%
Permanencia media de la direcciónsin datos
Promedio de permanencia en la Junta Directivasin datos

Actualizaciones recientes de la dirección

Recent updates

Subdued Growth No Barrier To Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) With Shares Advancing 30%

Nov 06
Subdued Growth No Barrier To Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) With Shares Advancing 30%

Lionco Pharmaceutical GroupLtd (SHSE:603669) Has Debt But No Earnings; Should You Worry?

Oct 29
Lionco Pharmaceutical GroupLtd (SHSE:603669) Has Debt But No Earnings; Should You Worry?

Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

May 10
Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump

Mar 12
There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump

CEO

Ling Ping Tao (54 yo)

no data

Permanencia

CN¥660,000

Compensación

Ms. Ling Ping Tao is General Manager of Lionco Pharmaceutical Group Co.,Ltd. and serves as its Chairman of the Board.